Cargando…

Impact of PCSK9 on CTRP9-Induced Metabolic Effects in Adult Rat Cardiomyocytes

The adipocytokine adiponectin and its structural homologs, the C1q/TNF-related proteins (CTRPs), increase insulin sensitivity, fatty acid oxidation and mitochondrial biogenesis. Adiponectin- and CTRP-induced signal transduction has been described to involve the adiponectin receptors and a number of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rohrbach, Susanne, Li, Ling, Novoyatleva, Tatyana, Niemann, Bernd, Knapp, Fabienne, Molenda, Nicole, Schulz, Rainer
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Physiology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7904879/ https://www.ncbi.nlm.nih.gov/pubmed/33643060 http://dx.doi.org/10.3389/fphys.2021.593862

Ejemplares similares

CTRP9 Mediates Protective Effects in Cardiomyocytes via AMPK- and Adiponectin Receptor-Mediated Induction of Anti-Oxidant Response
por: Niemann, Bernd, et al.
Publicado: (2020)

Autocrine effects of PCSK9 on cardiomyocytes
por: Wolf, Annemarie, et al.
Publicado: (2020)

Differential effects of right and left heart failure on skeletal muscle in rats
por: Knapp, Fabienne, et al.
Publicado: (2020)

Comparative Analysis of CTRP-Mediated Effects on Cardiomyocyte Glucose Metabolism: Cross Talk between AMPK and Akt Signaling Pathway
por: Li, Ling, et al.
Publicado: (2021)

Editorial: PCSK9: Importance in Physiology and Pathophysiology
por: Schulz, Rainer, et al.
Publicado: (2021)

PCSK9 in Myocardial Infarction and Cardioprotection: Importance of Lipid Metabolism and Inflammation
por: Andreadou, Ioanna, et al.
Publicado: (2020)

PCSK9 targets important for lipid metabolism
por: Schulz, Rainer, et al.
Publicado: (2017)

PCSK9 Inhibition: Insights From Clinical Trials and Future Prospects
por: Katzmann, Julius L., et al.
Publicado: (2020)

Effects of 6-months' Exercise on Cardiac Function, Structure and Metabolism in Female Hypertensive Rats–The Decisive Role of Lysyl Oxidase and Collagen III
por: Schreckenberg, Rolf, et al.
Publicado: (2017)

Saxagliptin but Not Sitagliptin Inhibits CaMKII and PKC via DPP9 Inhibition in Cardiomyocytes
por: Koyani, Chintan N., et al.
Publicado: (2018)

Molecular and cellular function of the proprotein convertase subtilisin/kexin type 9 (PCSK9)
por: Schulz, Rainer, et al.
Publicado: (2015)

Untypical Metabolic Adaptations in Spontaneously Hypertensive Rats to Free Running Wheel Activity Includes Uncoupling Protein-3 (UCP-3) and Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Expression
por: Wolf, Annemarie, et al.
Publicado: (2021)

Effect of Physical Activity on Plasma PCSK9 in Subjects With High Risk for Type 2 Diabetes
por: Mäkelä, Kari Antero, et al.
Publicado: (2019)

New Insights Into the Regulation of Lipoprotein Metabolism by PCSK9: Lessons From Stable Isotope Tracer Studies in Human Subjects
por: Ying, Qidi, et al.
Publicado: (2021)

Caloric restriction reduces sympathetic activity similar to beta-blockers but conveys additional mitochondrio-protective effects in aged myocardium
por: Niemann, Bernd, et al.
Publicado: (2021)

Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) Deletion but Not Inhibition of Extracellular PCSK9 Reduces Infarct Sizes Ex Vivo but Not In Vivo
por: Schreckenberg, Rolf, et al.
Publicado: (2022)

Pathogenic gain-of-function mutations in the prodomain and C-terminal domain of PCSK9 inhibit LDL binding
por: Sarkar, Samantha K., et al.
Publicado: (2022)

Oxidized low-density lipoprotein (oxLDL) affects load-free cell shortening of cardiomyocytes in a proprotein convertase subtilisin/kexin 9 (PCSK9)-dependent way
por: Schlüter, Klaus-Dieter, et al.
Publicado: (2017)

Physiological and therapeutic regulation of PCSK9 activity in cardiovascular disease
por: Glerup, Simon, et al.
Publicado: (2017)

Cardiomyocyte-specific PCSK9 deficiency compromises mitochondrial bioenergetics and heart function
por: Laudette, Marion, et al.
Publicado: (2023)

Ablation of Matrix Metalloproteinase-9 Prevents Cardiomyocytes Contractile Dysfunction in Diabetics
por: Prathipati, Priyanka, et al.
Publicado: (2016)

New Insights Into Implications of CTRP3 in Obesity, Metabolic Dysfunction, and Cardiovascular Diseases: Potential of Therapeutic Interventions
por: Guo, Bei, et al.
Publicado: (2020)

C1q/TNF-related protein 3 (CTRP3) and 9 (CTRP9) concentrations are decreased in patients with heart failure and are associated with increased morbidity and mortality
por: Gao, Chao, et al.
Publicado: (2019)

Circulating C1q complement/TNF-related protein (CTRP) 1, CTRP9, CTRP12 and CTRP13 concentrations in Type 2 diabetes mellitus: In vivo regulation by glucose
por: Bai, Bo, et al.
Publicado: (2017)

CTRP9 Mitigates the Progression of Arteriovenous Shunt-Induced Pulmonary Artery Hypertension in Rats
por: Guan, Hua, et al.
Publicado: (2021)

FOURIER & PCSK9 RNAi: Towards enhancing durability and efficacy of PCSK9 inhibitors
por: Hassan, Mohamed
Publicado: (2017)

The PCSK9 revolution and the potential of PCSK9-based therapies to reduce LDL-cholesterol
por: Seidah, Nabil G.
Publicado: (2017)

The Multifaceted Biology of PCSK9
por: Seidah, Nabil G, et al.
Publicado: (2021)

PCSK9 and triglyceride-rich lipoprotein metabolism
por: Druce, Irena, et al.
Publicado: (2015)

Putative therapeutic impacts of cardiac CTRP9 in ischaemia/reperfusion injury
por: Sadat‐Ebrahimi, Seyyed‐Reza, et al.
Publicado: (2022)

Impact of PCSK9 Immunization on Glycemic Indices in Diabetic Rats
por: Momtazi-Borojeni, Amir Abbas, et al.
Publicado: (2021)

Eligibility, Clinical Outcomes, and Budget Impact of PCSK9 Inhibitor Adoption: The CANHEART PCSK9 Study
por: Ko, Dennis T., et al.
Publicado: (2018)

The effect of PCSK9 immunization on the hepatic level of microRNAs associated with the PCSK9/LDLR pathway
por: Ataei, Sarina, et al.
Publicado: (2023)

Role of CTRP3, CTRP9 and MCP-1 for the evaluation of T2DM associated coronary artery disease in Egyptian postmenopausal females
por: Ahmed, Sara F., et al.
Publicado: (2018)

CTRP9 Ameliorates Atrial Inflammation, Fibrosis, and Vulnerability to Atrial Fibrillation in Post‐Myocardial Infarction Rats
por: Liu, Mingxin, et al.
Publicado: (2019)

PCSK9 Antibodies for the Treatment of Hypercholesterolemia
por: Gouni-Berthold, Ioanna, et al.
Publicado: (2014)

PCSK9 and Atherosclerosis - Lipids and Beyond
por: Shapiro, Michael D., et al.
Publicado: (2017)

An Update on the Role of PCSK9 in Atherosclerosis
por: Yurtseven, Ece, et al.
Publicado: (2020)

Naturally Occurring PCSK9 Inhibitors
por: Adorni, Maria Pia, et al.
Publicado: (2020)

PCSK9 Monoclonal Antibodies: An Overview
por: Kaddoura, Rasha, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_qphan4i59btj2fhff0l41u7p8i